{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:41:49Z","timestamp":1788316909503,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"am","delay-in-days":274,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.bcmd.2019.102392","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T11:29:23Z","timestamp":1575026963000},"page":"102392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Mastocytosis onset in a patient with treated hairy cell leukemia: Just a coincidence?"],"prefix":"10.1016","volume":"81","author":[{"given":"Alice","family":"Boil\u00e8ve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Contejean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Barreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lise","family":"Sourdeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Kosmider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Lheure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Bouscary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Grignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcmd.2019.102392_bb0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/asheducation-2015.1.98","article-title":"Diagnosis and management of mastocytosis: an emerging challenge in applied hematology","volume":"2015","author":"Valent","year":"2015","journal-title":"Hematology"},{"issue":"11","key":"10.1016\/j.bcmd.2019.102392_bb0010","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bcmd.2019.102392_bb0015","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcmd.2019.102392_bb0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.23380","article-title":"Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components","volume":"88","author":"Wang","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.bcmd.2019.102392_bb0025","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","article-title":"Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge","volume":"57","author":"Horny","year":"2004","journal-title":"J. Clin. Pathol."},{"issue":"5\u20136","key":"10.1016\/j.bcmd.2019.102392_bb0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428190009058500","article-title":"Clinical and biologic diversity of leukemias occurring in patients with mastocytosis","volume":"37","author":"Sperr","year":"2000","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.bcmd.2019.102392_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"issue":"5\u20136","key":"10.1016\/j.bcmd.2019.102392_bb0040","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/10428199709039049","article-title":"Systemic mast cell disease associated with hairy cell leukaemia","volume":"25","author":"Petrella","year":"1997","journal-title":"Leuk. Lymphoma"},{"issue":"45","key":"10.1016\/j.bcmd.2019.102392_bb0045","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.2174\/1381612822666160928121857","article-title":"Mast cell disorders in drug hypersensitivity","volume":"22","author":"Bonadonna","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.bcmd.2019.102392_bb0050","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bcmd.2019.102392_bb0055","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J. Pathol."},{"issue":"8","key":"10.1016\/j.bcmd.2019.102392_bb0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12032-014-0123-4","article-title":"Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis","volume":"31","author":"H\u00e4gglund","year":"2014","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.bcmd.2019.102392_bb0065","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.bcmd.2019.102392_bb0070","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bcmd.2019.102392_bb0075","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10069","key":"10.1016\/j.bcmd.2019.102392_bb0080","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.bcmd.2019.102392_bb0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428194.2011.565093","article-title":"Long-term results for pentostatin and cladribine treatment of hairy cell leukemia","volume":"52","author":"Dearden","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"18","key":"10.1016\/j.bcmd.2019.102392_bb0090","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.bcmd.2019.102392_bb0095","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.V128.22.1214.1214","article-title":"Vemurafenib plus rituximab in hairy cell leukemia: a promising chemotherapy-free regimen for relapsed or refractory patients","volume":"128","author":"Tiacci","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcmd.2019.102392_bb0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/bloodadvances.2018027466","article-title":"Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib","volume":"3","author":"Shenoi","year":"2019","journal-title":"Blood Adv."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979619303924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979619303924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:33:59Z","timestamp":1761050039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979619303924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":20,"alternative-id":["S1079979619303924"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2019.102392","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mastocytosis onset in a patient with treated hairy cell leukemia: Just a coincidence?","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2019.102392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102392"}}